NewDirectContract MCPSet up MCP →
DirectContract

Employer intelligence

Self-insured employers (platform)

DirectContract tracks 3 documented direct-contract arrangements involving Self-insured employers (platform) and providers including Eli Lilly (Zepbound / tirzepatide), Waltz Health, Henry Ford Health. The records span 2 markets and include Transparent Pricing structures, with primary sources and reported economics where available.

3

Tracked contracts

—

Covered lives represented

3

Active or expanded

—

Highest reported savings

Tracked arrangements

Eli Lilly (Zepbound / tirzepatide) ↔ Self-insured employers (platform)

United States · 2026-03

Eli Lilly launched a direct-to-employer platform for tirzepatide (Zepbound) in March 2026, enabling self-insured employers to access GLP-1 obesity treatment at transparent prices without PBM intermediaries. The model cuts spread pricing and allows employers to offer the drug as a defined benefit at a predictable cost.

Model: Transparent Pricing

Status: active

Lives: Not disclosed

Savings: Reduced GLP-1 costs by bypassing PBM spread pricing

Primary source ↗

Waltz Health ↔ Self-insured employers (platform)

United States · 2025-11

Waltz Health launched a direct-to-employer access model for GLP-1 obesity management medications in November 2025. The platform allows self-insured employers to offer tirzepatide and semaglutide at transparent, contracted prices without traditional PBM markup.

Model: Transparent Pricing

Status: active

Lives: Not disclosed

Savings: Lower net cost on obesity management drugs vs. traditional PBM

Primary source ↗
Explore all contractsGet the Friday briefing